IPHA - Innate Pharma S.A.
NASDAQ
->
Healthcare
->
Biotechnology
Marseille,
France
IPHA price evolution
IPHA
| (in millions $) | 30 Dec 2021 | 29 Sep 2021 | 29 Jul 2021 | 30 Mar 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $103.76 | $103.76 | $125.29 | $103.98 |
| Short term investments | $16.08 | $16.08 | $15.34 | $15.34 |
| Net receivables | $13.47 | $13.47 | $12.49 | $3.6 |
| Inventory | ||||
| Total current assets | $138.26 | $138.26 | $156.26 | $129.69 |
| Long term investments | $39.88 | $39.88 | $40.08 | $40.08 |
| Property, plant & equipment | $10.17 | $10.17 | $13.12 | $10.89 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $164.5 | |||
| Total investments | ||||
| Total assets | $267.5 | $267.5 | $320.76 | $266.22 |
| Current liabilities | ||||
| Accounts payable | $14.73 | $14.73 | $20.51 | $11.18 |
| Deferred revenue | $12.61 | |||
| Short long term debt | $29.94 | $29.94 | $1.18 | $1.18 |
| Total current liabilities | $79.89 | $79.89 | $51.35 | $42.62 |
| Long term debt | $11.49 | $11.49 | $17.45 | $12.03 |
| Total noncurrent liabilities | $108.49 | |||
| Total debt | ||||
| Total liabilities | $160.06 | $160.06 | $159.84 | $132.66 |
| Shareholders' equity | ||||
| Retained earnings | -$272.21 | -$272.21 | -$294.18 | -$244.15 |
| Other shareholder equity | $0.46 | $0.46 | $0.86 | $0.72 |
| Total shareholder equity | $107.44 | $107.44 | $133.56 | $133.56 |
| (in millions $) | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $103.76 | $136.79 | $202.89 | $152.31 |
| Short term investments | $16.08 | $14.85 | $15.98 | $15.22 |
| Net receivables | $13.47 | $21.81 | $18.74 | $146.64 |
| Inventory | ||||
| Total current assets | $138.26 | $173.45 | $237.6 | $319.64 |
| Long term investments | $39.88 | $38.93 | $37.01 | $35.18 |
| Property, plant & equipment | $10.17 | $11.69 | $11.67 | $10.22 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $153.04 | $183.41 | $155.39 | |
| Total investments | ||||
| Total assets | $267.5 | $307.42 | $401.36 | $451.22 |
| Current liabilities | ||||
| Accounts payable | $14.73 | $20.73 | $27.94 | $28.58 |
| Deferred revenue | $12.91 | $54.62 | $96.96 | |
| Short long term debt | $29.94 | $1.36 | $1.49 | $0.39 |
| Total current liabilities | $79.89 | $45.49 | $121.82 | $196.74 |
| Long term debt | $11.49 | $14.19 | $14.1 | $2.03 |
| Total noncurrent liabilities | $121.04 | $69.58 | $103.03 | |
| Total debt | ||||
| Total liabilities | $160.06 | $151.45 | $183.94 | $283.98 |
| Shareholders' equity | ||||
| Retained earnings | -$272.21 | -$220.46 | -$155.67 | -$134.79 |
| Other shareholder equity | $0.46 | $0.35 | -$0.47 | -$1.1 |
| Total shareholder equity | $107.44 | $155.98 | $217.42 | $167.24 |
| (in millions $) | 31 Jan 2022 | 29 Sep 2021 | 29 Jul 2021 | 30 Mar 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7.84 | |||
| Cost of revenue | $10.9 | |||
| Gross Profit | -$3.05 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $9.66 | |||
| Total operating expenses | $20.56 | |||
| Operating income | -$12.71 | |||
| Income from continuing operations | ||||
| EBIT | -$12.71 | |||
| Income tax expense | ||||
| Interest expense | -$0.08 | |||
| Net income | ||||
| Net income | -$11.86 | |||
| Income (for common shares) | -$11.86 | |||
| (in millions $) | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $24.7 | $70.45 | $85.81 | $93.95 |
| Cost of revenue | $47 | $58.61 | $78.84 | $69.56 |
| Gross Profit | -$22.3 | $11.84 | $6.97 | $24.4 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $25.52 | $31.25 | $25.8 | $18.14 |
| Total operating expenses | $72.53 | $89 | $112.87 | $88.81 |
| Operating income | -$47.83 | -$18.55 | -$27.05 | $5.15 |
| Income from continuing operations | ||||
| EBIT | -$47.83 | -$18.55 | -$27.05 | $5.15 |
| Income tax expense | -$0.33 | |||
| Interest expense | -$0.31 | -$0.34 | -$0.2 | -$0.1 |
| Net income | ||||
| Net income | -$52.81 | -$63.98 | -$20.76 | $3.05 |
| Income (for common shares) | -$52.81 | -$63.98 | -$20.76 | $3.05 |
| (in millions $) | 30 Dec 2021 | 29 Sep 2021 | 29 Jul 2021 | 30 Mar 2021 |
|---|---|---|---|---|
| Net income | -$28.58 | -$11.86 | ||
| Operating activities | ||||
| Depreciation | $1.08 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$37.55 | -$15.58 | ||
| Investing activities | ||||
| Capital expenditures | -$0.12 | |||
| Investments | ||||
| Total cash flows from investing | -$0.3 | -$0.12 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$0.56 | |||
| Total cash flows from financing | -$1.48 | -$0.61 | ||
| Effect of exchange rate | -$0.21 | -$0.09 | ||
| Change in cash and equivalents | -$39.54 | -$16.41 | ||
| (in millions $) | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 |
|---|---|---|---|---|
| Net income | -$52.81 | -$63.98 | -$20.76 | $3.05 |
| Operating activities | ||||
| Depreciation | $4.6 | $13.27 | $16.53 | $7.34 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$58.46 | -$51.77 | $34.92 | -$32.53 |
| Investing activities | ||||
| Capital expenditures | -$0.93 | -$0.91 | -$1.27 | -$0.87 |
| Investments | -$3 | $2 | $24.22 | |
| Total cash flows from investing | -$0.92 | -$13.37 | -$62.12 | $24.28 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | $26.63 | -$0.89 | $11.92 | -$1.34 |
| Total cash flows from financing | $26.82 | -$1.18 | $77.77 | $61.22 |
| Effect of exchange rate | -$0.48 | $0.22 | $0.01 | -$0.03 |
| Change in cash and equivalents | -$33.04 | -$66.1 | $50.57 | $52.95 |
News
|
3 Small-Caps That Might Be Acquisition Candidates
Motley Fool
9 May 2022
|
|
48 Stocks Moving In Friday's Mid-Day Session
Benzinga
29 Apr 2022
|
|
Nkarta Scores Huge Gain on Can
Guru Focus
25 Apr 2022
|
|
Cathie Wood Can't Get Enough of These 2 Biotech Stocks | The Motley Fool
The Motley Fool
31 Mar 2022
|
|
... Medicine Achieves its First Major Milestone in Fosun Pharma Collaboration with the Nomination of...
KCRG-TV9 Cedar Rapids
17 Feb 2022
|
|
20 Stocks Moving in Tuesday's Pre-Market Session
Benzinga
25 Jan 2022
|
|
AstraZeneca (AZN) Inks Deal to Develop ATTR-CM Candidate
MSN News
11 Jan 2022
|
|
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease...
Benzinga
5 Jan 2022
|
|
18 Stocks Moving in Monday's Pre-Market Session
Benzinga
3 Jan 2022
|
|
AstraZeneca (AZN) Closes Agreement for Eplontersen With Ionis
MSN News
31 Dec 2021
|
Fundamentals
| Market cap | $230.50M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 79.48M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 2.15 |
| Book/Share | 1.35 |
| Cash/Share | 1.31 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.49 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.73 |
| Quick ratio | N/A |